Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy

Lymphodepletion chemotherapy followed by infusion of CD19-specific chimeric antigen receptor–modified (CAR) T cells has produced impressive antitumor responses in patients with refractory CD19(+) B-cell malignancies but is often associated with cytokine release syndrome (CRS). Our understanding of C...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Hay, Kevin A., Hanafi, Laïla-Aïcha, Li, Daniel, Gust, Juliane, Liles, W. Conrad, Wurfel, Mark M., López, José A., Chen, Junmei, Chung, Dominic, Harju-Baker, Susanna, Cherian, Sindhu, Chen, Xueyan, Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Immunobiology and Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5701525/
https://ncbi.nlm.nih.gov/pubmed/28924019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-06-793141
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados